Survival outcomes of patients with uncommon EGFR mutations in surgically resected lung adenocarcinoma: A multi-institutional real-world database study (CReGYT-01 EGFR study) [0.03%]
罕见EGFR突变肺腺癌患者的生存结局：一项多中心真实世界数据库研究（CReGYT-01 EGFR研究）
Kazuki Hayasaka,Mototsugu Shimokawa,Naoki Haratake et al.
Kazuki Hayasaka et al.
Introduction: Uncommon epidermal growth factor receptor (EGFR) mutations (UCM) account for approximately 10% of EGFR-mutant lung adenocarcinoma (LUAD) cases; however, their prognostic impact remains unclear. This study ai...
Multi-omic screening for pleural mesothelioma in Asbestos-Exposed Populations: A literature review and Recommendations [0.03%]
多组学筛选在接触过石棉的人群中筛查胸膜间皮瘤：文献综述和建议
Kathleen Zwijsen,Ellen Heirwegh,Eline Schillebeeckx et al.
Kathleen Zwijsen et al.
Objectives: Pleural mesothelioma (PM) is an aggressive thoracic cancer related to historical exposure to asbestos fibres. Symptoms often appear at an advanced stage, leading to delayed diagnosis and dismal prognosis. Earl...
External evaluation of the Manchester score in a contemporary SCLC cohort [0.03%]
曼彻斯特评分在当代小细胞肺癌队列中的外部验证研究
Charlie Cunniffe,Matthew Sperrin,Gerard Walls et al.
Charlie Cunniffe et al.
Objectives: The Manchester Score, a prognostic model developed in 1987, was used to stratify patients with Small Cell Lung Cancer (SCLC) by mortality risk, including stage, performance status, and three blood tests as ris...
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors [0.03%]
一线ALK酪氨酸激酶抑制剂治疗的ALK阳性转移性非小细胞肺癌患者脑转移的发生率、患病率和临床影响：一项真实世界研究
Geoffrey Liu,Devin Abrahami,Priya Ramachandran et al.
Geoffrey Liu et al.
Introduction: This real-world study evaluated the incidence and clinical impact of brain metastases in patients with anaplastic lymphoma kinase-positive (ALK + ) metastatic non-small cell lung cancer (mNSCLC) receiving fi...
Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials [0.03%]
TP53分类对经治且驱动基因阴性的晚期非小细胞肺癌患者的临床影响：来自OAK和POPLAR随机临床试验的生物标志物分析
Deborah Di-Xin Zhou,Sarah J Lord,Frank Po-Yen Lin et al.
Deborah Di-Xin Zhou et al.
Background: In NSCLC, TP53 mutations are heterogeneous with varied effects on protein synthesis, function and clinical outcomes. We hypothesize that a refined classification of TP53 mutations, beyond binary categorization...
Is sublobar resection a valid option for radiologically pure-solid clinical stage IA non-small cell lung cancer?: insights from real-world data and current status [0.03%]
放射学纯固态临床期IA期非小细胞肺癌的亚肺叶切除术是否是一种有效的选择？：来自真实世界数据和当前状况的见解
Dong Woog Yoon,Sumin Shin,Chu Hyun Kim et al.
Dong Woog Yoon et al.
Objectives: We aimed to evaluate the oncologic outcomes of sublobar resection (SLR) compared with lobectomy in patients with radiologically pure-solid stage IA non-small cell lung cancer (NSCLC). ...
The role of APOBEC in early-stage epidermal growth factor receptor-mutant non-small cell lung cancer [0.03%]
APOBEC在表皮生长因子受体突变的早期非小细胞肺癌中的作用
Hyun Ae Jung,Jinyeong Lim,Yoon-La Choi et al.
Hyun Ae Jung et al.
Background: APOBEC plays a crucial role in the mutation process and immune response of non-small cell lung cancer (NSCLC). This study evaluated the role of the APOBEC mutation signature in early-stage epidermal growth fac...
Effect of treatment sequencing on outcome of patients with non-small cell lung cancer with a synchronous solitary extrathoracic metastasis [0.03%]
不同治疗模式对同步发生单发肺外转移非小细胞肺癌患者预后的影响
Mandy Jongbloed,Ronald A M Damhuis,Wouter H Van Geffen et al.
Mandy Jongbloed et al.
Currently, guidelines advise local radical treatment (LRT) to all disease sites in addition to systemic therapy in patients with synchronous oligometastatic non-small cell lung cancer (NSCLC). However, the best order of treatments is unknow...
Inavolisib for PIK3CA-mutant non-small cell lung cancer: A case report [0.03%]
PIK3CA突变非小细胞肺癌应用INAVOLISIB治疗的病例报告
Lei Cheng,Dongying Wang,Xueyan Zhang et al.
Lei Cheng et al.
Introduction: PIK3CA mutations are oncogenic drivers in 2-4% of non-small cell lung cancers (NSCLC), often co-occurring with other drivers and conferring therapeutic resistance. This report is unique in describing the eff...
Tarlatamab in routine clinical care: How much safety is enough? [0.03%]
tarlatamab在常规临床护理中的安全性评估：足够的安全标准是多少？
Ernest Nadal,Jordi Bruna
Ernest Nadal